Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis
| العنوان: | Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis |
|---|---|
| المؤلفون: | Masato Kono, Hideki Kusagaya, Sayomi Matsushima, Noriyuki Enomoto, Takafumi Suda, Masato Karayama, Yutaro Nakamura, Takashi Matsui, Masato Fujii, Yusuke Inoue, Naoki Inui, Hironao Hozumi, Tomoyuki Fujisawa, Kazuki Furuhashi, Koichi Miyashita, Mikio Toyoshima, Keigo Koda, Yuzo Suzuki, Shun Matsuura, Kazuhiro Asada, Hiroyuki Matsuda, Mitsuru Niwa |
| المصدر: | BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-9 (2021) BMC Pulmonary Medicine |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, B7-H1 Antigen, Diseases of the respiratory system, Japan, Carcinoma, Non-Small-Cell Lung, Internal medicine, Pleomorphic carcinoma, medicine, Humans, Propensity Score, Lung cancer, neoplasms, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, RC705-779, business.industry, Research, Large cell neuroendocrine carcinoma, Large cell, Not Otherwise Specified, Histology, Middle Aged, medicine.disease, Survival Analysis, Progression-Free Survival, Confidence interval, respiratory tract diseases, Programmed death ligand-1, Logistic Models, Treatment Outcome, Programmed death-1, Multivariate Analysis, Propensity score matching, Adenocarcinoma, Immunohistochemistry, Female, business, Not otherwise specified |
| الوصف: | Background Clinical efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC) with uncommon histology (uNSCLC) is unknown. Methods Patients with NSCLC treated with ICI monotherapy between January 2014 and December 2018 in 10 Japanese hospitals were retrospectively evaluated. The patients were divided into: (1) NSCLC with common histology (cNSCLC), defined as adenocarcinoma and squamous cell carcinoma; and (2) uNSCLC, defined as incompatibility with morphological and immunohistochemical criteria for adenocarcinoma or squamous cell carcinoma. Propensity score matching was performed to balance the two groups. Results Among a total of 175 patients included, 44 with uNSCLC (10 pleomorphic carcinomas, 9 large cell neuroendocrine carcinomas, 2 large cell carcinomas, and 23 not otherwise specified) and 44 with matched cNSCLC (32 adenocarcinomas and 12 squamous cell carcinomas) were selected for analyses. Median progression-free survival (PFS) (4.4 months, 95% confidence interval [CI] 1.8–7.7 months) and overall survival (OS) (11.4 months, 95% CI 7.4–27.4 months) in the uNSCLC patients were not significantly different from those in matched cNSCLC patients (5.4 months, 95% CI 3.1–7.6 months, p = 0.761; and 14.1 months, 95% CI 10.6–29.6 months, p = 0.381). In multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0–1 and programmed death ligand-1 (PD-L1) expression were predictive for PFS and OS in uNSCLC. Conclusions ICIs had similar clinical efficacy for treatment of uNSCLC and cNSCLC. Good ECOG-PS and PD-L1 expression were predictive for efficacy of ICIs in uNSCLC. |
| تدمد: | 1471-2466 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::239e036702c2f84764c80cd4e5076acd https://doi.org/10.1186/s12890-021-01681-6 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....239e036702c2f84764c80cd4e5076acd |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14712466 |
|---|